Barrett’s oesophagus

Endoscopic therapy of Barrett’s: what more do we need to know?

J-L Van Laethem, J Devière

Results emerging from endoscopic treatments to ablate Barrett’s oesophagus indicate that APC alone or ALA-PDT in combination with APC achieves complete clearance of Barrett’s epithelium in approximately two thirds of patients.

Over the past few years, different endoscopic ablative techniques have been used in combination with antireflux therapy with the aim of reversing Barrett’s oesophagus and replacing it with squamous epithelium. The end goal of these procedures is to impact directly on the risk of tumour development.

To date, most of the published results on ablative therapy in Barrett’s oesophagus have dealt with a single treatment modality, and long term results as well as the real impact on the course of the condition remain unanswered.

The most widely used and studied procedures are photochemical (that is, photodynamic therapy (PDT) using Photofin or more recently 5-aminolevulinic acid (5-ALA)1-10) and thermal (that is, argon plasma coagulation (APC)).1

The study by Hage and colleagues11 in this issue of Gut, is the first to compare two modalities [see page 785]. This was a well designed, prospective, randomised, three arm study involving 40 patients with non or low dysplastic Barrett’s oesophagus, randomised to treatment with ALA-PDT as a single dose of 100 J/cm² (n = 13), ALA-PDT as a fractionated dose of 20 and 100 J/cm² (n = 13), or APC 65 W for two sessions (n = 14). All patients received omeprazole 40 mg daily. After the designated treatment, any residual Barrett’s oesophagus was treated with additional sessions of APC.

The end points of the study were endoscopic reduction of the Barrett’s oesophagus surface and the microscopic presence or absence of intestinal metaplasia at different time points (that is, six weeks and 6, 12, 18, and 24 months). In the setting of endoscopic therapy of Barrett’s oesophagus, complete histological ablation of specialised metaplastic epithelium should be considered the unique relevant end goal of these procedures as only complete histological clearance will influence the risk of cancer in this condition. Even in this scenario, only long term studies (more than five years) will tell us if this type of treatment is effective in preventing the need for surveillance and ultimately in reducing the risk of cancer development.

The results provided by the present randomised study are relatively similar to those reported in previous ones which assessed a single modality, particularly with regard to treatment procedures, median length of Barrett’s oesophagus (3 cm), proton pump inhibitor therapy, and duration of follow up (12 months).1,11

Clearly, there was no significant difference between the two procedures at six weeks, with a complete histological response rate of 33% and 36% for the ALA-PDT fractionated dose and APC, respectively. As additional treatment with APC was permitted in both groups for residual metaplastic mucosa, interpreting the 12 month results is difficult. However, it is interesting to note that residual Barrett’s oesophagus was observed in only 10% of the ALA-PDT group and in 33% of the APC group, although the difference was not significant as the number of patients enrolled was relatively small.

The results from the ALA-PDT group compare favourably with previous reports: PDT is effective in eradicating high grade dysplasia or superficial tumours in 90–100% of cases but squamous re-epithelialisation was found in only two thirds of patients and was incomplete in all.1,11 The rate of residual Barrett’s oesophagus after eradication using APC ranged from 0% to 68% in various series1-5 after a mean follow up period of approximately 12 months. It is not easy to explain this high variability which could depend on the technical procedure, length of the abnormal mucosa, and perhaps most importantly acid suppressive maintenance therapy.

In long term follow up studies (median follow up 36 months), we and others have clearly identified the length of the Barrett’s segment and normalisation of acid exposure as the only independent predictive factors for sustained long term re-epithelialisation.7,9 However, other factors may be involved such as biliary reflux, or microenvironmental or genetic abnormalities.7,9-10

In summary, the study of Hage et al confirms results emerging from endoscopic treatments to ablate Barrett’s oesophagus: APC alone or ALA-PDT in combination with APC achieves complete clearance of Barrett’s epithelium in approximately two thirds of patients. The direct impact on the cancer risk in Barrett’s oesophagus is unknown. Given the risk of developing adenocarcinoma arising under squamous re-epithelialisation,11,12 the potential complications of such endoscopic therapies, and the high cost of such management, we should follow the authors’ recommendations of not using these techniques routinely. On the other hand, these modalities, especially PDT and its newer development in photosensitisation, offer fascinating perspectives for the curative management of early neoplastic changes and severe dysplasia arising in Barrett’s oesophagus.

Finally, these experimental groups of patients, having already received treatment to eradicate Barrett’s oesophagus, should be monitored in order to obtain valuable clinical information on the rate of tumour development over the next 10 years. All of these patients should be followed up with further endoscopic evaluations at five and 10 years.
Infliximab

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

W J Sandborn, E V Loftus

Patients with moderate to severely active Crohn’s disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin’s lymphoma

Infliximab, a monoclonal antibody to tumour necrosis factor (TNF) \( \alpha \), is an important advance in the treatment of Crohn’s disease.\(^6,7\) The efficacy of infliximab for the treatment of ulcerative colitis is still unclear.\(^8,9\) Infliximab was approved for the treatment of Crohn’s disease in 1998 based on a 12 week phase 2 trial in 108 patients\(^1\) (followed by a 36 week extension trial)\(^2\) and a small phase 3 trial in 94 patients,\(^3\) both of which showed compelling efficacy. Because of the possibility of open label crossover at week 4, 102 of 108 patients in the phase 2 trial received infliximab by week 12. Thus only six patients in the phase 2 study and 31 patients in the phase 3 study who received placebo were available for safety follow up without crossover to infliximab. Although not all patients enrolled in these studies were receiving concomitant corticosteroids and/or azathioprine or 6-mercaptopurine, regulatory approval in the USA was granted only in patients with moderate to severely active Crohn’s disease unresponsive to conventional therapy (not defined) and for fistulising Crohn’s disease; and in Europe in patients with moderate to severely active Crohn’s disease or fistulising Crohn’s disease unresponsive to a full and adequate course of corticosteroids and immunosuppressive therapy. These restrictions were, at least in part, a reflection of the uncertainties regarding safety. Subsequently, two blinded, placebo controlled, phase 4 maintenance trials (designed as infliximab withdrawal trials) were conducted in 573 patients with moderate to severely active Crohn’s disease\(^4,5\) and in 306 patients with fistulising Crohn’s disease.\(^6\) All patients in these two maintenance studies initially received at least one induction dose of infliximab. Thus safety data in patients with Crohn’s disease treated only with placebo who were naïve to infliximab was available in only 34 of 1081 patients enrolled in placebo controlled trials. Potential treatment emergent safety issues in the other 1047 patients treated with infliximab in these clinical trials included non-Hodgkin’s lymphoma in 2/1047 (0.2%), opportunistic infections in 3/1047 (0.3%) (tuberculosis \( n = 1 \); cytomegalovirus \( n = 1 \); cutaneous Nocardia \( n = 1 \)), serious infections which occurred at rates of 4% and 4.6% in the two large maintenance trials,\(^8\) serum sickness-like reactions in 19/1047 (1.8%),\(^8\) drug induced lupus in 2/1047 (0.2%),\(^8\) and death in 4/1047 (0.4%) patients, including two deaths from lymphoma and one death from sepsis that were potentially related to infliximab\(^7\) (one patient developed lymphoma during a maintenance trial and then died during follow up\(^8\)). Post-marketing safety reports or warnings from the US Food and Drug Administration have yielded additional information regarding the potential for opportunistic infections, including tuberculosis,\(^9\) disseminated histoplasmosis,\(^10\) coccidioidomycosis, listeriosis, and Pneumocystis carinii pneumonia,\(^\text{11}\) and possibly non-Hodgkin’s lymphoma.\(^12\) Many of these post-marketing events occurred in patients with rheumatoid arthritis who have a median age 20 years older than that of patients with Crohn’s disease.

In this issue of Gut, Ljung and colleagues\(^8\) report on the clinical benefit and toxicity associated with the use of infliximab in a population based cohort of 217 patients with inflammatory bowel disease (Crohn’s disease \( n = 191 \), ulcerative colitis \( n = 22 \), indeterminate colitis \( n = 4 \)) in Stockholm County, Sweden [see page 849]. Patients received a mean of 2.6 infusions of infliximab (range 1–11). Fifty four per cent of patients were also receiving azathioprine or 6-mercaptopurine, 51% were receiving corticosteroids, and 25% were receiving both. The authors reported that the clinical benefit observed in patients with Crohn’s disease was comparable with that reported in the controlled trials referenced above and in other uncontrolled reports of infliximab in clinical practice.\(^8\) The authors also reported that severe adverse events occurred in 41 (18.9%) patients (Crohn’s disease \( n = 35 \), ulcerative colitis \( n = 6 \)) including: non-Hodgkin’s lymphomas in 3/217 (1.4%) patients (Crohn’s disease \( n = 3 \)) of whom two died; severe infections in 18/217 (8.3%) patients (Crohn’s disease \( n = 11 \), ulcerative colitis \( n = 5 \)); serum sickness-like reaction in 5/217 (2.3%) (Crohn’s disease \( n = 5 \)); and drug induced lupus in 1/217 (0.5%) (Crohn’s disease \( n = 1 \)). The severe infections included opportunistic infection in 2/217 (0.9%) patients (listeriosis \( n = 1 \) in a patient with Crohn’s disease, Pneumocystis carinii \( n = 1 \) in a patient with ulcerative colitis who died) and fatal sepsis in 2/217 (0.9%) patients (Crohn’s disease \( n = 1 \),
ulcerative colitis n = 1). In total, 6/217 (2.8%) patients died in 28 months for a crude annual mortality of 1.2%: 3/191 (1.6%) patients with Crohn’s disease died (non-Hodgkin’s lymphoma n = 2, sepsis n = 1); 3/22 (13.6%) patients with ulcerative colitis died (sepsis n = 1, Pneumocystis carinii n = 1, pulmonary embolus n = 1). All patients who died were receiving corticosteroids and most were elderly; at least two of the three patients who developed lymphoma were receiving or had previously received azathioprine.

Another study recently reported the safety experience in 500 consecutive patients with Crohn’s disease treated with infliximab at the Mayo Clinic. Patients received a median of three infusions and had a median follow up of 17 months. Forty three patients (8.6%) experienced a serious adverse event of which 30 (6%) were considered to be possibly related to infliximab. Serum sickness-like disease occurred in 19/500 patients and was attributed to infliximab in 14 (2.8%). Three patients (0.6%) developed drug induced lupus. One patient (0.2%) developed a new demyelination disorder. Forty eight patients had an infectious event of which 41 (8.2%) were attributed to infliximab. Twenty patients (0.4%) had a serious infection: two fatal sepsis, eight pneumonias of which two were fatal, six viral infections, two abdominal abscesses requiring surgery, one arm cellulitis, and one histoplasmosis (opportunistic infection). Nine patients had a malignant disorder, three of which were possibly related to infliximab, including one lymphoma (0.2%). A total of 10 deaths were observed over a median of 17 months, yielding a crude annual mortality of 1.3%. For five of these patients (1%), the events leading to death were possibly related to infliximab. Most of the patients who died were elderly.

These three data sets (controlled clinical trials, Ljung et al study, Colombel et al study) show remarkable convergence for the frequency of the most important adverse events. Serious or severe infections occurred at a rate of 4.0–4.6% in clinical trials, 8.3% in the Ljung et al study, and 8.2% in the Colombel et al study. Opportunistic infection occurred at a rate of 0.3% in the clinical trials, 0.9% in the Ljung et al study, and 0.2% in the Colombel et al study. Serum sickness-like reactions occurred at a rate of 1.9% in the clinical trials, 2.3% in the Ljung et al study, and 2.8% in the Colombel et al study. Drug induced lupus occurred at a rate of 0.2% in the clinical trials, 0.5% in the Ljung et al study, and 0.6% in the Colombel et al study. Finally, death in patients with Crohn’s disease occurred at a crude annual rate of 0.4% in the clinical trials, 1.2% of patients in the Ljung et al study, and 1.3% of patients in the Colombel et al study. The mortality rate in these three data sets is comparable with what has previously been described in several studies of the natural history of Crohn’s disease. Non-Hodgkin’s lymphoma occurred at a rate of 0.2% in the clinical trials and in the Colombel et al study, and at a rate of 1.4% in the Ljung et al study. Based on these results from clinical trials, a referral centre, and a population based cohort, we can conclude that patients with moderate to severely active Crohn’s disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin’s lymphoma. However, it must be pointed out that all three data sets lack adequate controls, and one cannot be certain to what degree the potential bias of infliximab being given to the most refractory patients, and concomitant immunosuppressive therapy, may contribute to any possible risk.

Thus the important unanswered question is to what degree infliximab therapy caused or contributed to these serious adverse events and to the observed crude annual mortality rates? Population based studies in patients with Crohn’s disease have shown only a slightly increased mortality (with three exceptions where no increased mortality was reported) and no increased risk of non-Hodgkin’s lymphoma (with one exception). However, these population based studies have not provided mortality or lymphoma rates adjusted for patient age, disease severity, or concomitant therapy with corticosteroids and/or azathioprine or 6-mercaptopurine. Clinical trials and observational studies have reported that corticosteroids and azathioprine may result in abdominal abscess, sepsis, and death; and that azathioprine and 6-mercaptopurine may be associated with non-Hodgkin’s lymphoma. Thus the data reported in the clinical trials and by Ljung et al and Colombel et al must be interpreted with caution. At the present time all that we can really say is that patients with moderately to severely active Crohn’s disease who are failing therapy with corticosteroids and/or azathioprine or 6-mercaptopurine. Clinical trials and observational studies have reported that corticosteroids and azathioprine may result in serious infection, opportunistic infection, and possibly non-Hodgkin’s lymphoma. It is unclear if the crude annual mortality rate is increased or not. Whether these adverse outcomes are directly caused by or exacerbated by infliximab, or are the result of other important confounders such as age, severity of illness, concomitant therapy with corticosteroids, concomitant therapy with azathioprine or 6-mercaptopurine, and combination therapy with corticosteroids and azathioprine or 6-mercaptopurine, is impossible to determine from the available data. Preliminary data from one large registry study in 5000 patients has reported that the severity of illness and corticosteroids account for virtually all of the infections and any excess mortality in patients with Crohn’s disease treated with infliximab.

To definitively address these issues, population based studies of patients treated with infliximab adjusted for important confounders are needed. Patient registries containing comparator patients not treated with infliximab will also be useful in this regard. Placebo controlled trials with infliximab (without crossover of placebo patients to infliximab) in patients with mild to moderately active Crohn’s disease who are not receiving concomitant therapy with corticosteroids and/or immunosuppressives would also give a more clear signal regarding safety outcomes, but such studies may no longer be feasible. In general, clinicians should restrict the use of infliximab to patients with moderate to severely active Crohn’s disease who have failed conventional therapy such as corticosteroids and immunosuppressive therapy with azathioprine, 6-mercaptopurine, or methotrexate. Patients with ulcerative colitis and indeterminate colitis should not be treated with infliximab until definitive evidence of efficacy from placebo controlled trials is available.


Authors’ affiliations
W J Sandborn, E V Loftus, Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA

Correspondence to: Dr W J Sandborn, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.william@mayo.edu

Conflict of interest: Dr Sandborn has received research support from, served as a consultant for, and participated in continuing medical education events sponsored indirectly by Centocor Inc.

REFERENCES
The database regarding spontaneous bacterial peritonitis (SBP) has increased dramatically in the past 33 years since this phrase was first coined by Harold Conn.1 In the remote past this easily treatable cause of deterioration of patients with advanced cirrhosis was underdiagnosed and undertreated. This undoubtedly led to many unnecessary deaths, which were probably viewed as mysterious at the time.

Now we know that SBP is quite common, with a prevalence of >20% on admission to the hospital, prior to the era of prevention.2 We know who is at high risk—patients with cirrhosis and (a) prior SBP, (b) low protein ascites, or (c) gastrointestinal bleeding.3 We also know how to diagnose, treat, and even prevent this potentially fatal infection.3,4

Even the “spontaneous” nature of this infection has been largely resolved in recent years. We now know that the gut is the source of most of the bacteria that eventually cause SBP.5 As cirrhosis develops in animals, gram negative bacteria increase in numbers in the gut.6 We know that the gut of animals and patients with advanced cirrhosis is more permeable to bacteria than the normal gut and more permeable than the gut in less advanced cirrhosis.6,7

Once bacteria reach a critical concentration in the gut lumen, they “spill over” and escape the gut, “translocating” to mesenteric lymph nodes. Then they can enter lymph, blood, and eventually ascitic fluid.8 If the ability of the ascitic fluid to assist macrophages and neutrophils in killing the errant bacteria is deficient, uncontrolled growth occurs.9 This is SBP. In general, the animal or
patient dies if they develop this infection and it is not promptly diagnosed and treated.

Thus SBP is the result of failure of the gut to contain bacteria and failure of the immune system to kill the virulent bacteria once they have escaped the gut. Patients and animals have duplicative mechanisms of protection from bacteria. This makes great sense teleologically. Opsonins assist motile and fixed "professional" killers of bacteria, the neutrophils and Kupffer cells, respectively. Immune defenders against bacterial invasion include macrophages, dendritic cells, and natural killer cells. These cells synthesise proinflammatory cytokines and effector molecules which assist in killing bacteria.

Unfortunately, patients with advanced cirrhosis have been reported to have defects and dysfunction in many of these systems of protection. It is then no surprise that these patients are vulnerable to infection by their own gut flora. To make matters worse, some of the effector molecules and cytokines that help kill the bacteria have undesired side effects. Nitric oxide (NO) is one of these effector molecules. Tumour necrosis factor (TNF) is one of the relevant cytokines. NO is probably the long sought after antigen responsible for vasodilation that characterises advanced liver disease. Bacterial infection leads to further elevations in these molecules. NO and TNF are important mediators of the further vasodilatation and renal failure that too often accompany SBP.

The good news here is that selective intestinal decontamination with poorly absorbed antibiotics reduces gut bacterial counts, reduces translocation rates, can prevent SBP in high risk subgroups, and can improve the haemodynamic circulatory state of these patients. Based on the information presented above, one would predict that the presence of whole bacteria or DNA in serum and ascitic fluid would have consequences (for example, stimulation of immune defences, effector molecules, and cytokines). This could in turn impact on haemodynamics, renal function, and survival. These effector molecules and cytokines are two edged swords. They can protect from bacterial infection but they can also initiate a sequence of events than can lead to the patient's death.

The elegant study in this issue furtheres this line of investigation and provides the scientific rationale for new clinical studies, including a randomised controlled trial. The authors harvested peritoneal macrophages from patients with cirrhosis and ascites. Approximately one third of their patients had detectable bacterial DNA. They divided the patients into two groups: those with and without bacterial DNA in serum and ascitic fluid. They measured macrophage production of NO metabolites and cytokines, including TNF, and compared the results between the two groups. The authors convincingly demonstrate that peritoneal macrophages from patients with cirrhosis and bacterial DNA in serum and ascitic fluid are markedly activated, as evidenced by increased NO synthesising ability and enhanced cytokine production.

This study provides further insight into very early events in the pathogenesis of SBP. Pieces of bacteria commonly escape the gut and end up in blood and ascitic fluid. In the process, a complex sequence of events occurs. The immune system is stimulated to contain the bacterial colonisation and protect the host from fatal infection. However, as a consequence, the effector molecules and cytokines are increased, setting the stage for worsening of the haemodynamic status, development of functional renal failure, and the possibility of death.

Now that this new subset of patients with molecular evidence of translocation has been identified, it is perhaps time to perform a prospective study following those patients who are positive for bacterial DNA and determining if their risks of SBP, hepatoportal syndrome, and death are higher than those of DNA negative controls. If excessive morbidity and/or mortality are documented, the next step would be to conduct a randomised controlled trial of selective intestinal decontamination versus placebo in the DNA positive group and determine if hepatoportal syndrome and death can be prevented.

**REFERENCES**


www.gutjnl.com